StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Sanofi (SNY) Insulin Glargine + Lixisenatide NDA Accepted by FDA
February 22, 2016 8:04 AM
Sanofi (NYSE: SNY) announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Next Articles
Sanofi (SNY) Announces Plans to Reture Auvi-Q Rights to kaléo
February 23, 2016 4:56 PM
FDA Accepts Sanofi New Drug Application for Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide
February 22, 2016 8:00 AM